Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06902519 · ClinicalTrials.gov registry record · Phase 1
Study of GS-0151 in Participants With Rheumatoid Arthritis
A Phase 1 study of Rheumatoid Arthritis, sponsored by Gilead Sciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
- 20
- Study locations
NCT06902519 is a Phase 1 study of Rheumatoid Arthritis that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 75 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 10 states.
The verdict
NCT06902519, a Phase 1 study of Rheumatoid Arthritis, is actively recruiting participants, sponsored by Gilead Sciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG GS-0151
Study Locations (20)
Other
- ARENSIA Exploratory Medicine, LLC - Tbilisi
- Universitatsklinikum Koln - Cologne
- Krakenhaus Porz am Rhein - Cologne
- Hamburger Rheuma Forschungszentrum II - Hamburg
- Klinikum der Universitat Munchen - München
California
- University of California, San Diego - La Jolla
- Stanford University School of Medicine - Palo Alto
- Medvin Clinical Research - Tujunga
- Medvin Clinical Research - Whittier
Texas
- Accurate Clinical Management, LLC - Baytown
- Accurate Clinical Research, Inc - Houston
- Clinical Trials of Texas LLC, dba Flourish Research - San Antonio
Illinois
- Great Lakes Clinical Trials dba Flourish Research Chicago - Chicago
- DM Clinical Research - Melrose Park
Alabama
- Pinnacle Research Group, LLC - Anniston
Florida
- Clinical Research of West Florida, Inc - Clearwater
Louisiana
- Accurate Clinical Research, Inc - Lake Charles
Oklahoma
- Lynn Health Science Institute - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-05-14 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06902519
The ClinicalTrials.gov registry entry for NCT06902519 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06902519 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, California, Texas.
Frequently Asked Questions
What is clinical trial NCT06902519 about?
NCT06902519 is a clinical study titled "Study of GS-0151 in Participants With Rheumatoid Arthritis". The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple ...
What is the current status of trial NCT06902519?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2025-05-14. Estimated completion is 2027-03.
What conditions does trial NCT06902519 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT06902519?
The interventions under investigation include: Placebo (DRUG), GS-0151 (DRUG).
Who is sponsoring clinical trial NCT06902519?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06902519 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
-
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.